PFE — PFIZER INC (Healthcare >> Drug Manufacturers - General)
PFE FAQ
What is PFE's P/E ratio?
PFIZER INC (PFE) currently trades at a P/E ratio of 16.14.
What is PFE's ROE?
PFIZER INC reports a Return on Equity (ROE) of 8.31%.
What is PFE's dividend yield?
PFIZER INC offers a dividend yield of 6.69%.
What is PFE's Deepscope Quality Score?
Deepscope rates PFE's overall financial quality at 77 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PFE?
Deepscope's AI Timing Score for PFE is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PFE belong to?
PFIZER INC is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.
|
USD 26.04
Price
0.35
(1.36%)
Day Change
|
|
|---|
PFE, the overall quality is good ( Quality = 77) but the timing to buy is ...(Sign In to See)...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROE is relatively low.
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
52% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1563
|
| Magic Formula Rank by ROE |
1563
|
| Magic Formula Rank by ROIC |
1918
|
| Price | 26.04 |
| PBV / Sector |
1.63 / 2.84
|
| Earning Per Share | 1.32 |
| PE / Sector |
16.14 / 24.53
|
| PEG or PE/Growth / Sector |
0.27 / 0.08
GREAT
|
| Average 1M Daily Value |
729.43 M
|
| Average 1W Daily Value |
738.88 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
72% |
| Return to Investors |
|
100% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:57 |
| Symbol | PFE |
| Name | PFIZER INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 5,699.44 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 147,501.61 / 241,254.65 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
Phone: 212 733 2323
Website: https://www.pfizer.com
Employees: 75,000
Description: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google